Exp Mol Med.  2014 Jun;46(6):e100. 10.1038/emm.2014.26.

Benzylideneacetophenone derivatives attenuate IFN-gamma-induced IP-10/CXCL10 production in orbital fibroblasts of patients with thyroid-associated ophthalmopathy through STAT-1 inhibition

Affiliations
  • 1Department of Physiology and Global Top5 Research Program, Ewha Woman's University School of Medicine, Seoul, Korea. yc@ewha.ac.kr
  • 2Tissue Injury Defense Research Center, Ewha Woman's University School of Medicine, Seoul, Korea.
  • 3Department of Pharmacology, Ewha Woman's University School of Medicine, Seoul, Korea.
  • 4Department of Neuroscience, Ewha Woman's University School of Medicine, Seoul, Korea.
  • 5Department of Ophthalmology, Ajou University School of Medicine, Suwon, Korea. drkook@ajou.ac.kr

Abstract

The aim of the present study was to identify a new candidate anti-inflammatory compound for use in the active stage of thyroid-associated ophthalmopathy (TAO). Benzylideneacetophenone compound JC3 [(2E)-3-(4-hydroxy-3-methoxyphenyl)phenylpro-2-en-l-one] was synthesized based on a structural modification of yakuchinone B, a constituent of the seeds of Alpinia oxyphylla, which belongs to the ginger family (Zingiberaceae), has been widely used in folk medicine as an anti-inflammatory phytochemical. Orbital fibroblasts were primarily cultured from patients with TAO, and the potential of JC3 to suppress the interferon (IFN)-gamma-induced protein (IP)-10/CXCL10 production in these cells was determined. IFN-gamma strongly increased the level of IP-10/CXCL10 in orbital fibroblasts from patients with TAO. JC3 exerted a significant inhibitory effect on the IFN-gamma-induced increase in IP-10/CXCL10 in a dose-dependent manner; its potency was greater than that of an identical concentration of yakuchinone B with no toxicity to cells at the concentration range used. Moreover, the constructed dimer and trimer polystructures of JC3, showed greater potency than JC3 in suppressing the IFN-gamma-induced production of IP-10/CXCL10. JC3 significantly attenuated the IP-10/CXCL10 mRNA expression induced by IFN-gamma, and a gel-shift assay showed that JC3 suppressed IFN-gamma-induced DNA binding of signal transducer and activator of transcription-1 (STAT-1) in TAO orbital fibroblasts. Our results provide initial evidence that the JC3 compound reduces the levels of IP-10/CXCL10 protein and mRNA induced by IFN-gamma in orbital fibroblasts of TAO patients. Therefore, JC3 might be considered as a future candidate for therapeutic application in TAO that exerts its effects by modulating the pathogenic mechanisms in orbital fibroblasts.

Keyword

benzylideneacetophenone; CXCL10/IP-10; IFN-gamma; orbital fibroblasts; thyroid-associated ophthalmopathy; yakuchinone B

MeSH Terms

Cells, Cultured
Chalcone/chemical synthesis/*pharmacology
Chemokine CXCL10/genetics/*metabolism
Diarylheptanoids/chemistry/pharmacology
Fibroblasts/*drug effects/metabolism
Graves Ophthalmopathy/*metabolism
Humans
Interferon-gamma/*metabolism
Orbit/cytology
RNA, Messenger/genetics/metabolism
STAT1 Transcription Factor/genetics/*metabolism
Chalcone
Chemokine CXCL10
Diarylheptanoids
RNA, Messenger
STAT1 Transcription Factor
Interferon-gamma
Full Text Links
  • EMM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error